期刊
TRENDS IN CANCER
卷 4, 期 9, 页码 616-633出版社
CELL PRESS
DOI: 10.1016/j.trecan.2018.07.002
关键词
-
类别
资金
- MINECO/FEDER, UE [SAF-201563638R]
- Red Tematica de Investigacion Cooperativa sobre el Cancer (RTICC) [RD/12/0036/0033]
- Asociacion Espanola Contra el Cancer (AECC) [GCB141423113]
- Castilla-Leon Government [BIO/SA01/15, CSI049U16]
- MINECO [SAF2015-64556-R, RD12/0036/0002]
- Worldwide Cancer Research [14-1248]
- Ramon Areces Foundation
- AECC [GC16173472GARC]
- European Regional Development Fund
Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity of the kinases that participate in this pathway. Although promising, the efficacy of these therapies is short lived due to undesired toxicity and/or drug resistance problems. As an alternative path, new efforts are now being devoted to the targeting of protein-protein interactions (PPIs) involved in the flow of RAS-ERK signals. Many of these efforts have shown promising results in preclinical models. In this review, we summarize recent progress made in this area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据